NCT06877533
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06877533
Title A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 As Monotherapy and in Combination with Pembrolizumab or Other Anticancer Treatments in Participants with Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors iTeos Belgium SA
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Sarah Cannon Research Institute at HealthOne Denver Colorado 80218 United States Details
Florida Cancer Specialists (FSC SAC DDU) Sarasota Sarasota Florida 24232 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field